<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A case of <z:hpo ids='HP_0005305'>cerebral venous thrombosis</z:hpo> with familial antithrombin III (AT III) deficiency was reported and we discussed the <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy of <z:hpo ids='HP_0005305'>cerebral venous thrombosis</z:hpo> from the viewpoint of AT III </plain></SENT>
<SENT sid="1" pm="."><plain>The patient, a 17-year-old boy, was admitted to our clinic with severe bifrontal <z:hpo ids='HP_0002315'>headache</z:hpo>, generalized <z:mp ids='MP_0000947'>convulsions</z:mp> and progressive disturbance of consciousness </plain></SENT>
<SENT sid="2" pm="."><plain>He developed <z:hpo ids='HP_0002625'>deep vein thrombosis</z:hpo> in his right leg and <z:e sem="disease" ids="C0034065" disease_type="Disease or Syndrome" abbrv="">pulmonary emboli</z:e> two years earlier when he was placed on <z:chebi fb="5" ids="28304">heparin</z:chebi> and so forth, followed by <z:chebi fb="0" ids="10034">warfarin sodium</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="8" ids="10033">Warfarin</z:chebi> was terminated 9 months prior to his recent illness </plain></SENT>
<SENT sid="4" pm="."><plain>On neurological examination on admission, he was semicomatous with blurred disc margins, <z:e sem="disease" ids="C0271384" disease_type="Disease or Syndrome" abbrv="">roving eye movements</z:e> with right <z:e sem="disease" ids="C0271355" disease_type="Disease or Syndrome" abbrv="">abducens nerve palsy</z:e>, nuchal stiffness and right flaccid <z:hpo ids='HP_0002301'>hemiplegia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Left carotid angiogram and CT scan revealed extensive superior sagittal sinus <z:mp ids='MP_0005048'>thrombosis</z:mp>, complicated with hemorrhagic <z:mpath ids='MPATH_124'>infarcts</z:mpath> in bilateral frontal lobes </plain></SENT>
<SENT sid="6" pm="."><plain>When examined for coagulation studies, the patient and his father had decrease in AT III activity and antigen levels </plain></SENT>
<SENT sid="7" pm="."><plain>He was treated successfully with antiedematous agents and <z:chebi fb="0" ids="35623">anticonvulsants</z:chebi> during <z:hpo ids='HP_0011009'>acute</z:hpo> phase of illness </plain></SENT>
<SENT sid="8" pm="."><plain>He was thereafter placed on <z:chebi fb="8" ids="10033">warfarin</z:chebi> 5-6 mg/day with no further clinical thromboembolic event for 2 years 9 months </plain></SENT>
<SENT sid="9" pm="."><plain>There was no <z:hpo ids='HP_0000707'>neurological abnormality</z:hpo> when he was last examined, although he was treated with <z:chebi fb="0" ids="39867">valproic acid</z:chebi> 1,200 mg/day and phenytoin 250 mg/day to control occasional adversive <z:hpo ids='HP_0001250'>seizures</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>A coagulation study following infusion of 5,000 units of AT III was carried out </plain></SENT>
<SENT sid="11" pm="."><plain><z:chebi fb="8" ids="10033">Warfarin</z:chebi> was discontinued the day before the study </plain></SENT>
<SENT sid="12" pm="."><plain>0.64 U/kg of AT III administration resulted in a 1% increase in AT III level after the infusion </plain></SENT>
<SENT sid="13" pm="."><plain>The biological half life of AT III was 14.4 hours.(ABSTRACT TRUNCATED AT 250 WORDS) </plain></SENT>
</text></document>